Bristol-Myers Squibb Company
News and overview for Bristol-Myers Squibb Company
Bristol-Myers Squibb to split off its holdings in Mead Johnson Nutrition
News-Medical.Net | 8 days 23 hours 13 minutes ago
Bristol-Myers Squibb Company (NYSE: BMY) today announced it will split off its holdings in Mead Johnson Nutrition Company. The company expects the split-off to be a tax-advantaged way to further deliver value to Bristol-Myers Squibb shareholders. The split-off is expected to be net cash flow positive to the BioPharma business and accretive to earnings per share beginning in 2010.
Bristol-Myers Squibb and Alder Biopharmaceuticals collaborate in development of novel biologic for rheumatoid arthritis
News-Medical.Net | 14 days 18 hours 14 minutes ago
Bristol-Myers Squibb Company (NYSE:BMY) and Alder Biopharmaceuticals, Inc., today announced a global agreement for the development and commercialization of ALD518, a novel biologic that has completed Phase IIa development for the treatment of rheumatoid arthritis.
Asterand extends collaboration with Bristol-Myers Squibb
Business Weekly (U.K.) | 1 day 18 hours 12 minutes ago
Asterand, the Cambridge company specialising in human tissue for drug discovery and development has extended its collaboration with Bristol-Myers Squibb for access to Asterand's products and services for up to three years.
Bristol-Myers Squibb Announces Split-Off of Mead Johnson [Press Release]
Business Wire | 9 days 7 hours 32 minutes ago
Bristol-Myers Squibb Company (NYSE: BMY) today announced it will split off its holdings in Mead Johnson Nutrition Company. The company expects the split-off to be a tax-advantaged way to further deliver value to Bristol-Myers Squibb shareholders. The split-off is expected to be net cash flow positive to the BioPharma business and accretive to earnings per share beginning in 2010.
Bristol-Myers faces growing competition for key drugs as it reports 3Q results -- South Florida Sun-Sentinel.com
Sun-Sentinel (Fort Lauderdale, Fla.) | 34 days 15 hours 58 minutes ago
NEW YORK (AP) — Bristol-Myers Squibb Co. , the world's No. 15 drug maker by revenue, reports earnings for the third quarter on Thursday morning. The following is a summary of key developments and analyst opinion related to the period.
Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement on Rheumatoid Arthritis Biologic [Press Release]
Business Wire | 14 days 19 hours 32 minutes ago
Bristol-Myers Squibb Company (NYSE:BMY) and Alder Biopharmaceuticals, Inc., today announced a global agreement for the development and commercialization of ALD518, a novel biologic that has completed Phase IIa development for the treatment of rheumatoid arthritis.
Bristol-Myers faces growing competition for key drugs as it reports 3Q results
Orlando Sentinel (Fla.) | 34 days 16 hours 1 minute ago
NEW YORK (AP) — Bristol-Myers Squibb Co. , the world's No. 15 drug maker by revenue, reports earnings for the third quarter on Thursday morning. The following is a summary of key developments and analyst opinion related to the period.
U.S. Food and Drug Administration Approves ABILIFY (aripiprazole) for the Treatment of Irritability Associated with Autistic Disorder in Pediatric Patients (Ages 6 to 17 Years) [Press Release]
Business Wire | 4 days 7 hours 42 minutes ago
Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ABILIFY® (aripiprazole) for the treatment of irritability associated with autistic disorder in pediatric patients ages 6 to 17 years, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods.
Asterand Announces Extension of Agreement with Bristol-Myers Squibb [Press Release]
Business Wire | 1 day 18 hours 32 minutes ago
Asterand plc (LSE: ATD), a leading provider of human tissue and human tissue-based services to pharmaceutical and biotechnology companies engaged in drug discovery research, today announced that it has extended its collaboration with Bristol-Myers Squibb Company (NYSE: BMY) for access to Asterand's products and services for up to three years. The agreement will focus on access to Asterand's PhaseZERO® drug discovery services and Asterand's XpressBANKTM of human tissue and clinical samples for...
Bristol-Myers Squibb to split off of Mead Johnson
MarketWatch | 4 days 14 hours 25 minutes ago
Drug giant Bristol-Myers Squibb Co. /quotes/comstock/13!bmy/quotes/nls/bmy (BMY 24.15, +0.12, +0.50%) said on Sunday it would split off its Mead Johnson Nutrition Co. /quotes/comstock/13!mjn/quotes/nls/mjn (MJN 43.66, -0.09, -0.21%) business so that it can focus on its bio-pharmaceutical business.
Exelixis and Bristol-Myers Squibb Report New Phase 2 Data for XL184 in Patients With the Most Common and Aggressive Form of Brain Cancer [Press Release]
Business Wire | 32 days 9 hours 2 minutes ago
Exelixis, Inc. (Nasdaq:EXEL) and Bristol-Myers Squibb Company (NYSE:BMY) today reported updated phase 2 clinical data which show that XL184 demonstrated activity in patients with glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.
Bristol-Myers Squibb and ZymoGenetics Present Final Phase 1b Results for PEG-Interferon Lambda in Hepatitis C [Press Release]
Business Wire | 24 days 10 hours 2 minutes ago
Bristol-Myers Squibb Company (NYSE: BMY) and ZymoGenetics, Inc. (NASDAQ: ZGEN) today presented final results from a Phase 1b clinical trial of PEG-Interferon lambda administered with ribavirin in relapsed and treatment-naïve hepatitis C virus (HCV) patients. The poster included data on 56 patients in the study. Antiviral activity was observed at all dose levels tested. The results will be presented at the American Association for the Study of the Liver Diseases annual meeting in Boston on Nov...
Bristol-Myers Squibb to split off of Mead Johnson - MarketWatch
MarketWatch | 9 days 3 hours 22 minutes ago
Under the terms of the deal, New York-based Bristol, which has an 83% economic interest in Mead, will give Bristol shareholders roughly $1.11 in Mead shares for each $1 in Bristol shares they tender. The ratio will be determined by a 10% discount to the daily volume-weighted average prices of Bristol-Myers Squibb and Mead Johnson common shares over a three-day period in early December.
AMRI receives $750,000 milestone payment from Bristol-Myers Squibb
News-Medical.Net | 21 days 21 hours 14 minutes ago
AMRI (NASDAQ: AMRI) announced today that a third compound being developed under its license and research agreement with Bristol-Myers Squibb Company (NYSE: BMY) will proceed into preclinical development. AMRI will receive a $750,000 payment from Bristol-Myers Squibb for the completion of this milestone, marking the fifth milestone payment in the ongoing research collaboration between the two companies.
Third Compound from AMRI Bristol-Myers Squibb Collaboration Selected for Preclinical Development [Press Release]
Business Wire | 22 days 18 hours 32 minutes ago
AMRI (NASDAQ: AMRI) announced today that a third compound being developed under its license and research agreement with Bristol-Myers Squibb Company (NYSE: BMY) will proceed into preclinical development. AMRI will receive a $750,000 payment from Bristol-Myers Squibb for the completion of this milestone, marking the fifth milestone payment in the ongoing research collaboration between the two companies.
Company Overview
| Company: | Bristol-Myers Squibb Company |
|---|---|
| Industry: | Pharmaceuticals Manufacturers |
| Website: | http://www.bms.com |
Pharmaceutical giant Bristol-Myers Squibb (BMS) makes big bucks on matters of the heart. The company's blockbuster cardiovascular line-up includes heart disease drug Plavix, as well as Pravachol (which lowers cholesterol) and Avapro (for hypertension). BMS also makes antipsychotic medication Abilify and drugs in a number of other therapeutic categories, particularly oncology, virology (including HIV), and autoimmune disease. Through its Mead Johnson subsidiary, BMS makes Enfamil infant formula and other nutritional products for children. The company, which has more than 30 manufacturing plants worldwide and 10 R&D centers in five countries, sells its products globally; the US accounts for about half of sales.
Key Numbers
| Sales in U.S. Dollars (mil.) | 20,597 (2008) |
|---|---|
| One-year % Growth in Sales | 6.5 (2008) |
| Net Income in U.S. Dollars (mil.) | 5,247 (2008) |
| One-year % Growth in Net Income | 142.4 (2008) |
| Number of Employees | 35,000 (2008) |
| One-year % Growth in Number of Employees | -16.7 (2008) |
| Fiscal Year-End | December |